Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 Stocks Investors Are Watching Closely This Week.
Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry of positive developments, including a “buy” recommendation for its stock and the start of a series of clinical trials for its pancreatic cancer treatment candidate vopimetostat..
In a market report during the week, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for Tango Therapeutics Inc., following improvements in its earnings performance last year, having narrowed its net losses by 22 percent to $101.59 million from $130.3 million in 2024.
Photo by Pietro Jeng on Pexels
Total revenues, on the other hand, jumped by 48.3 percent to $62.38 million from $42.07 million year-on-year.
However, net loss in the fourth quarter widened by 26 percent to $38.7 million from $30.76 million, having earned no revenues during the period, versus a $5.4 million revenue in the same period a year earlier.
For this year, Tango Therapeutics Inc. is targeting to kick off a number of clinical trials to test its drug candidate vopimetostat in combination with multiple inhibitors for the treatment of pancreatic cancer.
It recently clinched a partnership with Erasca to jointly study the combination of vopimetostat with ERAS-0015 in treating pancreatic cancer.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
